Molecular Partners AG

Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced a comprehensive, peer-reviewed publication of preclinical data supporting MP0533's proposed unique mechanism of action (MoA) for the treatment of acute myeloid leukemia (AML) in Cancer Immunology Research, a journal of the American Association for Cancer Research. The publication collates and discusses multiple studies undertaken to characterize MP0533's preclinical profile and evaluate its therapeutic potential.

Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533's Proposed Mechanism of Action

First international chapter of Life Science Cares established in Switzerland – bringing hearts and minds together by empowering the life sciences industry to support local communities First international chapter of Life Science Cares established in Switzerland – bringing hearts and minds together by empowering the life sciences industry to support local communities

Life Science Cares Launches in Switzerland

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners  AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that all motions proposed by the Board of Directors at the Annual General meeting were approved by the shareholders of the Company by a wide majority.

Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Molecular Partners  AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today published the invitation to the Annual General Meeting 2024.

Molecular Partners Publishes Invitation to Annual General Meeting 2024

Molecular Partners AG (MOLN) Q4 2023 Earnings Call Transcript

Research & Development Highlights Presented encouraging initial data from first four dosing cohorts of ongoing Phase 1/2a trial of MP0533 for patients with relapsed/refractory AML and AML/MDS at the ASH Annual Meeting, reporting an acceptable safety profile and initial anti-tumor activity Introduced the Switch-DARPin concept and platform at PEGS Europe. In January 2024, introduced the first multispecific Switch-DARPin program, targeting cKIT x CD16a x CD47, as a next-generation conditioning regimen for hematopoietic stem cell transplantation Presented positive preclinical data supporting the Radio-DARPin Therapy (RDT) platform and expansion of the RDT pipeline at multiple leading scientific conferences In January 2024, announced a strategic collaboration agreement with Orano Med to co-develop 212Pb-based RDTs for multiple oncology targets, including DLL3 In January 2024, presented preclinical RDT data from the DLL3 program showing enhanced tumor uptake and reduced kidney absorption Presented updated positive data from the Phase 1 trial of MP0317 for patients with advanced solid tumors at the SITC Annual Meeting, demonstrating CD40 activation in the tumor microenvironment while maintaining a favorable safety profile Leadership & Governance: Dr. Philippe Legenne, M.D.

Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Molecular Partners  AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that a putative class action complaint against the Company, its directors, and certain of its executive officers (the defendants) has been dismissed in the Company's favor, and the case has been ordered closed.

Molecular Partners Announces Dismissal of Class Action Lawsuit

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Molecular Partners  AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that it will issue its fourth quarter and full year financial results for 2023 on March 14, which will be followed by a conference call the next day to discuss the results.

Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced it will present a business overview and provide its 2024 outlook at the 42nd Annual J.P. Morgan Healthcare Conference.

Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., and PARIS, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, and Orano Med, a pioneer in targeted alpha therapy, have announced a collaboration to develop novel Radio-DARPin therapeutics (RDTs) that use Orano Med's 212Pb radioisotope as a payload to selectively kill cancer cells. Both companies will leverage their unique capabilities to enable rapid clinical development and agree to share costs for preclinical and clinical development for multiple oncology targets, the first of which is DLL3.

Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place from January 8-11, 2024 in San Francisco, CA. In addition, members of Molecular Partners' leadership team will participate in upcoming investor events in Switzerland during January 2024. Conference Presentation Details

Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 10, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today presented positive initial clinical data from its ongoing Phase 1/2a trial of MP0533, a novel tetra-specific T cell engager, in a poster at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. These data, which highlight encouraging initial safety and antitumor activity, expand upon those previously disclosed in the conference abstract.

Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will present on several of its programs at the 15th Annual Protein & Antibody Engineering European Summit (PEGS Europe), which runs November 14-16 in Lisbon, Portugal. The presentation will focus on the multiple ways Molecular Partners has designed DARPins to activate the immune system against cancer only under certain conditions. This conditional activation is intended to focus immune attack more specifically against tumor cells and minimize damage to healthy cells, a major challenge for current oncology drugs and development efforts.

Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will present additional positive data from its Phase 1 study of MP0317 in patients with advanced solid tumors at the 2023 Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being held November 1–5 in San Diego, California. MP0317 is a CD40 agonist designed to activate immune cells specifically within the tumor microenvironment (TME) by anchoring to fibroblast activation protein (FAP).

Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will present preliminary data from its ongoing Phase 1/2a trial of MP0533, a novel tetra-specific T cell engager at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held from December 9–12 in San Diego, California. MP0533 is in development for the treatment of patients with relapsed/refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndrome (AML/MDS).

Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that the Company will participate in a fireside chat at the TD Cowen 7th Annual Fall Oncology Innovation Summit on Friday, November 3, 2023 at 9:00 a.m. ET. Presenting on behalf of Molecular Partners will be Patrick Amstutz, Chief Executive Officer, and Dr. Philippe Legenne, acting CMO.

Molecular Partners to Participate in the TD Cowen 7th Annual Fall Oncology Innovation Summit

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR:  Molecular Partners AG  (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biopharmaceutical company developing a class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced corporate highlights and unaudited financial results for the third quarter of 2023.

Molecular Partners Interim Management Statement Q3 2023: Continued Validation Seen Across the DARPin Portfolio

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biopharmaceutical company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announces new data from its Radio-DARPin Therapy (RDT) platform pertaining to potential efficacy of the approach and building on prior engineering achievements that boosted its renal safety profile. These data will be presented at the European Association of Nuclear Medicine (EANM) Annual Meeting, held September 9–13 in Vienna, Austria and can be accessed here.

Molecular Partners Presents New Data on its Radio DARPin Therapy (RDT) Platform at the EANM 2023 Annual Meeting

Phase 1/2a clinical trial of tetraspecific T cell engager candidate MP0533 initiated in patients with relapsed/refractory AML and MDS/AML; dosing ongoing in the 4th dose cohort; initial data expected in Q4 2023

Molecular Partners Reports H1 2023 Corporate Highlights and Financials

RDT platform offers unique approach for tailored delivery of radioactive payloads to solid tumors RDT platform is focused on improving both tumor-targeting efficiency and safety over historic protein-based radioligand approaches ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 27, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, has announced it will present on its Radio DARPin Therapy (RDT) Platform at the 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting being held from June 24-27 in Chicago, Illinois.

Molecular Partners to Present on its Radio DARPin Therapy (RDT) Platform at SNMMI 2023

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 19, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that the Company will present in a fireside chat at the TD Cowen Radiopharmaceutical Innovation Summit on Tuesday, June 20, 2023 at 12:00 p.m. ET. Presenting on behalf of Molecular Partners will be Patrick Amstutz, Chief Executive Officer, and Daniel Steiner, SVP Research.

Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit

MP0317 demonstrates tumor-localized CD40 activation in tumor biopsies through target occupancy and immune cell activation

Molecular Partners to Present Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 ASCO Annual Meeting

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 16, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that Patrick Amstuts, Chief Executive Officer, will participate in the 2023 RBC Capital Markets Global Healthcare Conference, in-person, May 16-17, 2023.

Molecular Partners to Participate in RBC Capital 2023 Global Healthcare Conference

MP0533: Phase 1 trial of MP0533 for AML ongoing; initial recruitment is progressing well, and site expansion is ongoing; initial clinical results on track for Q4 2023

Interim Management Statement Q1 2023 of Molecular Partners: Well Capitalized to Pursue Highly Differentiated DARPin Portfolio Strategy

Molecular Partners: Sellers Have Disappeared, Enterprise Value Below Zero.

News for Molecular Partners AG Stock (MOLN)